Brentuximab Vedotin With Dacarbazine or Nivolumab Is Viable Option for Older Patients With cHL Ineligible for Chemotherapy
Researchers sought to evaluate long-term follow-up data among patients who have been prescribed BV-dacarbazine therapy among older individuals with untreated cHL.